Print

Purpose

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of TRD

Exclusion Criteria

  • Other comorbidities

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Low dose 		Low dose Psilocybin
  • Drug: Psilocybin
    Dose-finding
Experimental
Medium dose 		Medium dose Psilocybin
  • Drug: Psilocybin
    Dose-finding
Experimental
High dose 		High dose Psilocybin
  • Drug: Psilocybin
    Dose-finding

More Details

Status
Completed
Sponsor
COMPASS Pathways

Study Contact

Detailed Description

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.